Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
NEW YORK and LONDON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer. Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. Multiple IND’s, NDA/BLA filings and/or defense and multiple successful launches. From 2010 to 2020, Dr Graham was VP of Strategic Program Direction, Immunology and Inflamm
[Read more]
| Impact snapshot | Event time: | TLSA | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
TLSA alerts
TLSA alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSA alerts
High impacting TIZIANA LIFE SCIENCES PLC news events
Weekly update
A roundup of the hottest topics
TLSA
News
- Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021GlobeNewswire
- Tiziana Life Sciences to Present at Biotech Showcase Digital 2021GlobeNewswire
- Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in BrazilGlobeNewswire
- Tiziana Life Sciences PLC (<a href="https://www.marketbeat.com/stocks/NASDAQ/TLSA/price-target/">NASDAQ: TLSA</a>) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.MarketBeat
- Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Publication of ProspectusGlobeNewswire
- More
TLSA
SEC Filings
- 1/13/21 - Form 6-K
- 1/11/21 - Form 6-K
- 1/11/21 - Form 6-K
- TLSA's page on the SEC website
- More